← Back to Search

Exercise for Non-Small Cell Lung Cancer

N/A

Waitlist Available

Led By Michael J. Toth, Ph.D.

Research Sponsored by University of Vermont

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up difference between the change in the exercised and non-exercised leg from baseline to 8 weeks

Awards & highlights

Study Summary

This trialwill examine how cancer treatment affects muscle size and function in human patients, with a goal of understanding the underlying factors.

Eligible Conditions

Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ difference between the change in the exercised and non-exercised leg from baseline to 8 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~difference between the change in the exercised and non-exercised leg from baseline to 8 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and difference between the change in the exercised and non-exercised leg from baseline to 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Cross-sectional area of skeletal muscle fibers

Mitochondrial content

Mitochondrial function

+1 more

Secondary outcome measures

Whole muscle isokinetic function

Whole muscle isometric function

Whole muscle size

Trial Design

1Treatment groups

Experimental Treatment

Group I: ExerciseExperimental Treatment1 Intervention

Lung cancer patients will undergo unilateral resistance exercise 3 times per week for 8 weeks during cancer treatment, while the other leg remains unexercised and will serve as a within-subject control.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Exercise

2016

Completed Phase 1

~760

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of VermontLead Sponsor

266 Previous Clinical Trials

3,743,680 Total Patients Enrolled

University of South CarolinaOTHER

211 Previous Clinical Trials

120,448 Total Patients Enrolled

Michael J. Toth, Ph.D.1.02 ReviewsPrincipal Investigator - University of Vermont

University of Vermont

2 Previous Clinical Trials

60 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the recruitment process for this trial still open?

"Clinicaltrials.gov affirms that this medical trail is actively recruiting patients and has been since July 1st, 2016 with their latest update issued on October 31st, 2022."

Answered by AI

What is the total enrollment for this clinical research project?

"Affirmative, according to the information on clinicaltrials.gov this study is currently recruiting volunteers. It was first posted on July 1st 2016 and last updated at the end of October 2022. The trial needs 20 participants from a single medical centre for completion."

Answered by AI

Is this medical trial only applicable to individuals over a certain age?

"This medical trial seeks to enroll patients aged 50-75. For those under 18, there are 75 trials, while 1677 studies accept participants over 65 years old."

Answered by AI

Is it possible for me to partake in this investigation?

"This medical study aims to recruit 20 individuals, ranging from 50-75 years old, suffering from atrophy. Other prerequisites for inclusion are an expected life expectancy of more than 6 months and a Karnofsky's performance score no lower than 70%."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Skeletal Muscle Atrophy and Dysfunction in Human Cancer

Michael J. Toth, Ph.D. 2016. "Skeletal Muscle Atrophy and Dysfunction in Human Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02949076.